RxDoctor Payments Data

Caroline Foote, MD

Cardiovascular Disease · Winchester, MANPI 1730207325

Payments from drug & device makers

$129in general payments, 2019–2025

Across 7 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$68
  • Pfizer$21
  • Astellas Pharma US Inc$21
  • Novo Nordisk$20

What the payments were for

  • Food & beverage$129100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC4$68
Pfizer1$21
Astellas Pharma US Inc1$21
Novo Nordisk1$20

How this compares

$129 in reported general payments places this provider in the 15th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$228,553
Medicare patients
2,325
Services billed
4,654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban411$390,940
VyndamaxTafamidis11$242,170
XareltoRivaroxaban81$66,151
EntrestoSacubitril/Valsartan21$23,700
JardianceEmpagliflozin32$23,682
JanuviaSitagliptin Phosphate25$14,725
Repatha SureclickEvolocumab11$13,082
Metoprolol Succinate519$10,997
Wixela InhubFluticasone Propion/Salmeterol36$5,873
Atorvastatin Calcium319$4,884
Rosuvastatin Calcium128$4,579
Valsartan78$2,969
Eplerenone28$2,225
Diltiazem 24hr Er (Cd)Diltiazem Hcl68$2,102
Lisinopril274$1,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$21$633,110422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Winchester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →